Clinical trial · Observational
Spinal Abnormalities in Neurofibromatosis Type 1 (NF1)
NCT00844129CI-TRIAL-00032768SpinecompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the incidence and clinical history of neurofibromatosis type 1-related spinal abnormalities.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neurofibromatosis Type 1 | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Neurofibromatosis Type 1
- description
- Children with Neurofibromatosis Type 1
Primary outcomes (1)
- measure
- Scoliosis and it's progression
- timeFrame
- 4 years
Secondary outcomes (1)
- measure
- Differences in other bone health variables as measured by thoracic MRIs, Dexa (xray measuring bone density), pQCT (a cross sectional picture of the tibia), urine analysis, and scoli series (xrays to look for scoliosis).
- timeFrame
- 4 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 6 Years
- Maximum age
- 9 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of NF1 * Age greater than 6 years at time of enrollment * Age less than 9 year and 1 day at time of enrollment * Tanner Stage not greater than 1 Exclusion Criteria: * Prior surgical repair of spine * Short-segment (4-6 vertebrae) curve with a Cobb angle of 45°or more * Hormone replacement therapy * Chronic steroid use * Tibial pseudarthrosis * Other chronic medical problems known to influence bone health (i.e. diabetes mellitus, cerebral palsy, etc.)
References
Publications (0)
Data not yet available
No reference posted for this study.